Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10968906 | Vaccine | 2011 | 8 Pages |
Abstract
An investigational, formalin-inactivated Rift Valley fever (RVF) vaccine, known as The Salk Institute-Government Services Division (TSI-GSD) 200 vaccine, was administered to 1860 at-risk subjects (5954 doses) between 1986 and 2004 as a three-dose primary series (days 0, 7, and 28) followed by booster doses as needed for declining titers. An initial positive serological response (PRNT80 â¥Â 1:40) to the primary series was observed in 90% of subjects. Estimate of the PRNT80 response half-life in initial responders to the primary series by Kaplan-Meier plot was 315 days after the primary series dose 3. Differences in a serological response were observed at 2 weeks after dose 3 of the primary series between vaccine lots and for gender (women > men); a trend was observed for age (<40 years). When response to the primary series was measured by PRNT50 titer â¥1:40, nearly all subjects (99.1%) responded. In individuals not initially responding to the primary series (PRNT80 < 1:40), a response was observed in most subjects after receiving only one booster dose. Immune response (all subjects) to subsequent booster doses for a declining titer (PRNT80 < 1:40) was 98.4%. The vaccine was well-tolerated; vaccine-related adverse reactions were generally mild and self-limited. Differences in adverse events were observed with vaccine lot and sex. The data support the safety and immunogenicity of the inactivated RVF vaccine, and may serve as a standard of comparison for immunogenicity and safety for future RVF vaccines.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Janice M. Rusnak, Paul Gibbs, Ellen Boudreau, Denise P. Clizbe, Phillip Pittman,